Want to join the conversation?
$ABBV said Humira delivered global operational growth of more than 17% in 2Q16. In rheumatology, Humira is the number one prescribed biologic and the company continues to grow its share position in the face of new competition. In dermatology and gastro, Humira holds a strong market leadership position, demonstrating double-digit growth YoverY.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.